Vaccination against SARS Cov 2 in teens with juvenile arthritis
SARS Cov2 Vaccination in Adolescents From 12 to 18 With Juvenile Idiopathic Arthritis in Angers, Nantes and Rennes : Acceptance and Safety.
Nantes University Hospital · NCT05547451
This study looks at how many teens with juvenile arthritis in France are getting vaccinated against COVID-19 and what factors affect their vaccination choices.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 12 Years to 18 Years |
| Sex | All |
| Sponsor | Nantes University Hospital (other) |
| Locations | 1 site (Nantes, Loire-Atlantique) |
| Trial ID | NCT05547451 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the vaccination coverage of SARS Cov 2 among adolescents aged 12 to 18 with juvenile idiopathic arthritis in France. It will involve reviewing medical records and distributing questionnaires to families to gather information on vaccination motives, obstacles, and the safety of the vaccine in this specific population. The study will also explore the impact of vaccination on the management of juvenile arthritis. The goal is to understand the factors influencing vaccination rates in this group.
Who should consider this trial
Good fit: Ideal candidates are adolescents aged 12 to 18 diagnosed with juvenile idiopathic arthritis who were followed up in 2021 and 2022.
Not a fit: Patients under 12 years old will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve vaccination rates and health outcomes for adolescents with juvenile idiopathic arthritis.
How similar studies have performed: Previous studies have indicated that vaccination is safe and well-tolerated in this population, suggesting a potential for success in understanding vaccination coverage.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients from 12 to 18 years old, on January the 1st 2022 * Patients followed up from juvenile arthritis * Patients followed up in 2021 and 2022 Exclusion Criteria: * Patients under 12 years old.
Where this trial is running
Nantes, Loire-Atlantique
- CHU de Nantes — Nantes, Loire-Atlantique, France (RECRUITING)
Study contacts
- Study coordinator: Soizic TIRIAU, Dr
- Email: soizic.tiriau@chu-nantes.fr
- Phone: 02 76 64 39 57
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis, SARS Cov2 vaccination, juvenile idiopathic arthritis, paediatric, safety, acceptance